HC Wainwright Comments on OmniAb’s Q1 Earnings (NASDAQ:OABI)

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for OmniAb in a research report issued on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.15) for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.57) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.27) EPS.

Separately, Benchmark cut their price target on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a report on Thursday.

OmniAb Stock Up 11.5 %

Shares of OmniAb stock opened at $2.53 on Monday. The business has a fifty day simple moving average of $3.34 and a 200-day simple moving average of $3.76. OmniAb has a fifty-two week low of $2.23 and a fifty-two week high of $5.63. The firm has a market cap of $357.28 million, a price-to-earnings ratio of -4.08 and a beta of -0.14.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million during the quarter, compared to analyst estimates of $10.13 million. During the same period last year, the company posted ($0.14) EPS.

Hedge Funds Weigh In On OmniAb

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new stake in shares of OmniAb in the fourth quarter worth $38,000. Choreo LLC purchased a new position in OmniAb during the 4th quarter valued at about $41,000. Rangeley Capital LLC acquired a new position in shares of OmniAb in the 4th quarter valued at about $41,000. KLP Kapitalforvaltning AS purchased a new stake in shares of OmniAb in the fourth quarter worth approximately $49,000. Finally, Walleye Capital LLC acquired a new stake in shares of OmniAb during the third quarter worth approximately $61,000. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other OmniAb news, CFO Kurt A. Gustafson sold 7,255 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total transaction of $26,625.85. Following the sale, the chief financial officer now owns 206,211 shares in the company, valued at approximately $756,794.37. The trade was a 3.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John L. Higgins acquired 125,750 shares of OmniAb stock in a transaction on Thursday, March 20th. The shares were purchased at an average cost of $2.35 per share, with a total value of $295,512.50. Following the completion of the purchase, the director now directly owns 2,762,887 shares of the company’s stock, valued at approximately $6,492,784.45. This represents a 4.77 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 112,260 shares of company stock worth $376,601. Insiders own 8.60% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.